NRX Pharmaceuticals- Warrants (24/05/2026) Return on Equity

NRX Pharmaceuticals- Warrants (24/05/2026) posts a ROE of 13811.76%. That is above the Healthcare sector average of 22.01%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 22.01% is typical. NRX Pharmaceuticals- Warrants (24/05/2026)'s 13811.76% is higher that level. That is roughly 62653.1% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

NRX Pharmaceuticals- Warrants (24/05/2026)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 13811.76%; use YoY and peer views to separate noise from signal.

Context for NRXPW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.01%), and (3) consistency with growth and profitability. This page covers the first two; NRX Pharmaceuticals- Warrants (24/05/2026)'s other metric pages and overview cover the third.

Judging NRX Pharmaceuticals- Warrants (24/05/2026) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 13811.76% here, then scan peer and history charts to see if the gap is persistent.